|
Market Closed -
Nasdaq
16:00:00 2025-11-18 EST
|
5-day change | 1st Jan Change | ||
| 42.98 USD | +0.35% |
|
-.--% | - |
| 05-18 | Endologix LLC acquired Pounce? Thrombectomy System from Surmodics, Inc. | CI |
| 12-09 | Surmodics, Inc. acquired certain assets from Biocoat, Incorporated. | CI |
| Fiscal Period: September | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -0.48 | 1.43 | -7.82 | 2.04 | -0.67 | |||||
Return on Total Capital | -0.61 | 1.8 | -9.97 | 2.53 | -0.8 | |||||
Return On Equity % | 0.89 | 3.13 | -21.95 | -1.35 | -9.67 | |||||
Return on Common Equity | 0.89 | 3.13 | -21.95 | -1.35 | -9.67 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 30.95 | 36.64 | 29.01 | 81.17 | 73.81 | |||||
SG&A Margin | 29.93 | 30.03 | 46.96 | 39.13 | 42.15 | |||||
EBITDA Margin % | 6.34 | 11.58 | -12.95 | 10.65 | 5.35 | |||||
EBITA Margin % | 1.32 | 6.9 | -17.69 | 7.09 | 1.47 | |||||
EBIT Margin % | -1.32 | 3.95 | -22.1 | 4.23 | -1.54 | |||||
Income From Continuing Operations Margin % | 1.18 | 4.03 | -27.29 | -1.16 | -9.15 | |||||
Net Income Margin % | 1.18 | 4.03 | -27.29 | -1.16 | -9.15 | |||||
Net Avail. For Common Margin % | 1.18 | 4.03 | -27.29 | -1.16 | -9.15 | |||||
Normalized Net Income Margin | -0.64 | 2.26 | -14.06 | 1.39 | -1.89 | |||||
Levered Free Cash Flow Margin | 7.43 | 4.73 | -6.74 | 10.64 | 5.44 | |||||
Unlevered Free Cash Flow Margin | 7.51 | 4.91 | -6.36 | 12.01 | 6.96 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.58 | 0.58 | 0.57 | 0.77 | 0.69 | |||||
Fixed Assets Turnover | 3.04 | 3.23 | 3.16 | 4.43 | 4.42 | |||||
Receivables Turnover (Average Receivables) | 6.12 | 7 | 5.91 | 7.32 | 6.03 | |||||
Inventory Turnover (Average Inventory) | 12.52 | 10.47 | 7.64 | 1.87 | 2.2 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 4.58 | 2.36 | 1.8 | 3.62 | 3.96 | |||||
Quick Ratio | 4.09 | 2.07 | 1.35 | 2.89 | 3.09 | |||||
Operating Cash Flow to Current Liabilities | 0.74 | 0.52 | -0.54 | 0.44 | 0.01 | |||||
Days Sales Outstanding (Average Receivables) | 59.77 | 52.15 | 61.77 | 49.85 | 60.69 | |||||
Days Outstanding Inventory (Average Inventory) | 29.24 | 34.87 | 47.79 | 194.88 | 166.27 | |||||
Average Days Payable Outstanding | 9.84 | 8.93 | 11.81 | 39.97 | 31.71 | |||||
Cash Conversion Cycle (Average Days) | 79.18 | 78.09 | 97.74 | 204.75 | 195.25 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 2.88 | 9.78 | 13.66 | 27.73 | 27.96 | |||||
Total Debt / Total Capital | 2.8 | 8.91 | 12.02 | 21.71 | 21.85 | |||||
LT Debt/Equity | 2.55 | 2.28 | 3.55 | 27 | 27.08 | |||||
Long-Term Debt / Total Capital | 2.48 | 2.07 | 3.12 | 21.14 | 21.17 | |||||
Total Liabilities / Total Assets | 22.34 | 28.01 | 31.55 | 35.44 | 33.41 | |||||
EBIT / Interest Expense | -9.41 | 13.4 | -36.93 | 1.61 | -0.55 | |||||
EBITDA / Interest Expense | 49.71 | 41.85 | -19.8 | 4.45 | 2.36 | |||||
(EBITDA - Capex) / Interest Expense | 22.11 | 24.82 | -25.44 | 3.61 | 1.37 | |||||
Total Debt / EBITDA | 0.57 | 1.06 | -1.25 | 2.14 | 3.98 | |||||
Net Debt / EBITDA | -8.67 | -1.94 | 0.35 | -0.78 | -0.82 | |||||
Total Debt / (EBITDA - Capex) | 1.28 | 1.78 | -0.97 | 2.64 | 6.84 | |||||
Net Debt / (EBITDA - Capex) | -19.49 | -3.27 | 0.28 | -0.96 | -1.41 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -5.21 | 10.83 | -4.93 | 32.65 | -4.91 | |||||
Gross Profit, 1 Yr. Growth % | -13.17 | 31.22 | -24.72 | 35.18 | -13.54 | |||||
EBITDA, 1 Yr. Growth % | -57.57 | 102.46 | -206.33 | -209.13 | -52.22 | |||||
EBITA, 1 Yr. Growth % | -86.79 | 480.86 | -343.76 | -153.17 | -80.27 | |||||
EBIT, 1 Yr. Growth % | -118.24 | -432.13 | -631.53 | -125.37 | -134.71 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -85.21 | 277.29 | -743.71 | -94.37 | 651.43 | |||||
Net Income, 1 Yr. Growth % | -85.21 | 277.29 | -743.71 | -94.37 | 651.43 | |||||
Normalized Net Income, 1 Yr. Growth % | -112.28 | -489.54 | -691.92 | -113.08 | -229.46 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -85.45 | 275 | -753.33 | -94.39 | 645.45 | |||||
Accounts Receivable, 1 Yr. Growth % | -19.88 | 17.97 | 8.04 | 6.14 | 24.23 | |||||
Inventory, 1 Yr. Growth % | 32.55 | 13.31 | 74.84 | 25.55 | 2.22 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 9.62 | -0.26 | -5.36 | -5.74 | -3.55 | |||||
Total Assets, 1 Yr. Growth % | 5.57 | 15.3 | -18.62 | 17.29 | -3.86 | |||||
Tangible Book Value, 1 Yr. Growth % | 10.31 | -36.61 | -31.15 | 28.38 | -0.14 | |||||
Common Equity, 1 Yr. Growth % | 6.97 | 6.89 | -22.62 | 10.63 | -0.84 | |||||
Cash From Operations, 1 Yr. Growth % | 74.3 | 9.84 | -211.92 | -161.05 | -97.64 | |||||
Capital Expenditures, 1 Yr. Growth % | -38.8 | 43.8 | -36.16 | -13.41 | 19.67 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -149.05 | -29.45 | -235.47 | -311.03 | -51.37 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -149.96 | -27.56 | -223.15 | -350.46 | -44.93 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 8 | 2.5 | 2.65 | 12.3 | 12.31 | |||||
Gross Profit, 2 Yr. CAGR % | 5.52 | 6.74 | -0.61 | 10.93 | 8.11 | |||||
EBITDA, 2 Yr. CAGR % | -8.59 | -7.31 | 46.73 | 7.72 | -27.79 | |||||
EBITA, 2 Yr. CAGR % | -39.95 | -12.41 | 276.29 | 13.85 | -67.61 | |||||
EBIT, 2 Yr. CAGR % | 27.96 | -22.16 | 320.17 | 16.12 | -70.32 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -49.8 | -25.29 | 392.82 | -39.79 | -34.95 | |||||
Net Income, 2 Yr. CAGR % | -49.8 | -25.29 | 392.82 | -39.79 | -34.95 | |||||
Normalized Net Income, 2 Yr. CAGR % | -27.48 | -30.83 | 380.18 | -12.02 | -58.85 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -51.49 | -26.15 | 394.97 | -39.45 | -35.32 | |||||
Accounts Receivable, 2 Yr. CAGR % | 24.61 | -2.78 | 12.9 | 7.09 | 14.83 | |||||
Inventory, 2 Yr. CAGR % | 21.88 | 22.55 | 40.75 | 48.16 | 13.29 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 4.01 | 4.56 | -2.85 | -5.55 | -4.65 | |||||
Total Assets, 2 Yr. CAGR % | 1.4 | 10.33 | -3.13 | -2.3 | 6.19 | |||||
Tangible Book Value, 2 Yr. CAGR % | 19.07 | -16.38 | -33.94 | -5.98 | 13.23 | |||||
Common Equity, 2 Yr. CAGR % | 9.85 | 6.93 | -9.06 | -7.48 | 4.73 | |||||
Cash From Operations, 2 Yr. CAGR % | -35.86 | 38.37 | 10.88 | -17.34 | -88 | |||||
Capital Expenditures, 2 Yr. CAGR % | -36.46 | -6.18 | -4.19 | -25.65 | 1.79 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -38.53 | -41.18 | -2.24 | 67.73 | 1.3 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -38.17 | -39.84 | -5.55 | 75.62 | 17.45 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 9.07 | 8.93 | -0.04 | 11.81 | 6.24 | |||||
Gross Profit, 3 Yr. CAGR % | -0.91 | 13.47 | -4.99 | 54.19 | 2.09 | |||||
EBITDA, 3 Yr. CAGR % | -22.53 | 19.15 | -2.97 | 32.94 | -17.85 | |||||
EBITA, 3 Yr. CAGR % | -49.67 | 27.94 | 23.2 | 95.99 | -36.53 | |||||
EBIT, 3 Yr. CAGR % | -44.65 | 75.86 | 47.68 | 64.84 | -22.35 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -34.11 | -1.67 | 53.15 | 11 | 39.66 | |||||
Net Income, 3 Yr. CAGR % | -34.11 | -1.67 | 53.15 | 11 | 39.66 | |||||
Normalized Net Income, 3 Yr. CAGR % | -48.8 | 27 | 41.48 | 44.47 | 0.07 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -34.9 | -4.09 | 52.74 | 11.2 | 39.82 | |||||
Accounts Receivable, 3 Yr. CAGR % | 24.1 | 22.35 | 0.7 | 10.6 | 12.52 | |||||
Inventory, 3 Yr. CAGR % | 19.27 | 18.96 | 37.96 | 35.49 | 30.92 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 12.44 | 2.57 | 1.14 | -3.82 | -4.89 | |||||
Total Assets, 3 Yr. CAGR % | 7.3 | 5.84 | -0.32 | 3.25 | -2.82 | |||||
Tangible Book Value, 3 Yr. CAGR % | 12.45 | -3.5 | -21.62 | -17.56 | -4.07 | |||||
Common Equity, 3 Yr. CAGR % | 5.52 | 8.85 | -4 | -2.92 | -5.32 | |||||
Cash From Operations, 3 Yr. CAGR % | -0.1 | -23.26 | 28.92 | -9.13 | -74.74 | |||||
Capital Expenditures, 3 Yr. CAGR % | -17.05 | -16.57 | -17.48 | -7.37 | -12.87 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 5.83 | -35.64 | -22.32 | 26.06 | 11.01 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 6.25 | -34.81 | -23.62 | 30.73 | 19.32 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 8.91 | 8.06 | 6.45 | 10.27 | 4.73 | |||||
Gross Profit, 5 Yr. CAGR % | -4.58 | -1.69 | -0.79 | 32.49 | 22.44 | |||||
EBITDA, 5 Yr. CAGR % | -25.61 | -14.35 | 0.02 | 14.44 | -13.79 | |||||
EBITA, 5 Yr. CAGR % | -44.73 | -21.24 | 12.54 | 22.11 | -27.8 | |||||
EBIT, 5 Yr. CAGR % | -44.42 | -28.04 | 24.52 | 48.96 | -22.28 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -37.68 | -15.76 | 47.35 | -19.19 | 8.74 | |||||
Net Income, 5 Yr. CAGR % | -37.68 | -15.76 | 47.35 | -19.19 | 8.74 | |||||
Normalized Net Income, 5 Yr. CAGR % | -47.2 | -29.04 | 25.35 | 9.66 | -13.67 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -38.37 | -16.96 | 46.55 | -20.2 | 8.32 | |||||
Accounts Receivable, 5 Yr. CAGR % | 13.01 | 18.81 | 19.49 | 16 | 6.13 | |||||
Inventory, 5 Yr. CAGR % | 14.9 | 13.56 | 27.44 | 29.87 | 27.5 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 20.25 | 10.66 | 6.05 | -0.76 | -1.22 | |||||
Total Assets, 5 Yr. CAGR % | 11.32 | 7.93 | 3 | 2.5 | 2.24 | |||||
Tangible Book Value, 5 Yr. CAGR % | 2.24 | -0.11 | -9.1 | -4.5 | -9.2 | |||||
Common Equity, 5 Yr. CAGR % | 7.36 | 5.57 | -0.57 | 2 | -0.6 | |||||
Cash From Operations, 5 Yr. CAGR % | -1.38 | -9.37 | 4.15 | -20.95 | -50.13 | |||||
Capital Expenditures, 5 Yr. CAGR % | 14.36 | -8.41 | -12.13 | -20.33 | -10.25 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -14.27 | -24.31 | 2.53 | -5.42 | -13.73 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -14.07 | -23.73 | 1.36 | -3.1 | -9.27 |
- Stock Market
- Stocks
- SRDX Stock
- Financials SurModics
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















